Hereditary Cancer Testing

Myriad’s hereditary cancer tests provide vital information to help people with a family history of disease understand their own risk of developing the disease. With this information, they can take steps to prevent the disease, delay the onset of disease, or catch the disease at an earlier stage where outcomes are better.

Many cancers are caused by mutated genes we inherit from our parents. The discovery of genes involved in cancer allows us to test for cancer causing changes in these genes. If a person has certain genetic changes passed on from their parents, they are at a much higher risk of getting cancer than people who do not have these changes. Because of this higher risk, healthcare providers and their patients may choose to take measures to reduce their risk of developing cancer. There are effective options to help lower a patient’s risk of cancer such as more intensive screening for cancer, preventive medication and risk reducing surgeries. Once the potential risk of cancer is identified, the healthcare provider and the patient can choose the best way to delay or even possibly prevent the development of certain cancers.

Myriad’s hereditary cancer testing products have been used to help millions of people with a strong family or personal history of cancer. These families usually have cancers that occur at an earlier age (e.g. below 50), occur in several family members or occur multiple times in the same individual. These cancers can be found on either the father’s side of the family or the mother’s side.

Myriad offers testing for several inherited cancers including breast, ovarian, colon, uterine and skin (melanoma) cancer. Healthcare providers and their patients use the information provided by Myriad to make better healthcare choices. This information can help improve health and quality of life while reducing healthcare costs.

To learn more about each of our Hereditary Cancer Testing products, simply click on a product below:

A 25-gene panel for the identification of clinically significant mutations impacting inherited risks for eight important cancers.

A predictive medicine product for hereditary breast and ovarian cancer.

BRACAnalysis® testing assesses a woman’s risk of developing hereditary breast or ovarian cancer based on detection of mutations in the BRCA1  and BRCA2 genes. This test has become the standard of care in identification of individuals with hereditary breast and ovarian cancer.

A predictive medicine product for Lynch syndrome.

COLARIS® testing assesses a persons risk of developing hereditary colorectal cancer and a woman’s risk of developing hereditary uterine cancer. COLARIS detects disease-causing mutations in the MLH1, MSH2, MSH6, PMS2, EPCAM and MYH  genes which are responsible for the majority of Lynch syndrome.

A predictive medicine product for adenomatous polyposis colon cancer syndromes.

COLARIS AP® testing assesses a persons risk of developing hereditary colorectal polyps and cancer. COLARIS AP detects mutations in the APC and MYH genes, which cause adenomatous polyposis colon cancer syndromes, including familial adenomatous polyposis (FAP), attenuated FAP (AFAP), and MYH -associated polyposis (MAP).

A predictive medicine product for hereditary melanoma.

MELARIS® testing assesses a persons risk of developing hereditary melanoma. This test detects inherited mutations in the p16 gene (also called CDKN2A or INK4A), which are associated with hereditary melanoma.

A predictive medicine product for hereditary pancreatic and related cancers.

PANEXIA® testing assesses a persons risk of developing hereditary pancreatic cancer. PANEXIA offers insight about the risk of future hereditary cancers for patients and their families. PANEXIA analyzes the PALB2 and BRCA2 genes, the two genes most commonly mutated in families with hereditary pancreatic cancer.